ヒト培養細胞由来Ｂ型肝炎ワクチンの有用性の検討

DOI Web Site 参考文献16件
  • 藤瀬 清隆
    東京慈恵会医科大学附属柏病院消化器・肝臓内科
  • 春日 葉子
    東京慈恵会医科大学附属柏病院消化器・肝臓内科
  • 鈴木 憲治
    東京慈恵会医科大学附属柏病院消化器・肝臓内科
  • 内藤 嘉彦
    東京慈恵会医科大学附属柏病院消化器・肝臓内科
  • 小林 正之
    東京慈恵会医科大学附属柏病院血液・腫瘍内科
  • 久保 政勝
    東京慈恵会医科大学附属柏病院小児科

書誌事項

タイトル別名
  • Effectiveness of a Human Cell Culture-Derived Hepatitis B Vaccine
  • ヒト バイヨウ サイボウ ユライ Bガタ カンエン ワクチン ノ ユウヨウセイ ノ ケントウ

この論文をさがす

抄録

We plan to introduce an adsorbed hepatitis B (HB) vaccine derived from human cell culture for mass inoculation of our hospital personnel and students of the attached school of nursing (student nurses). To assess the effectiveness of the new HB vaccine, the titer of acquired antibody to hepatitis B surface antigen (anti-HBs) and the side effects of the vaccine were compared with those of a conventional HB vaccine that has been used for the same purpose in the past. The student nurses (Group M) and the hospital personnel (Group B) underwent mass inoculation with the HB vaccine in the 2000 academic year, with three intramuscular doses of a human cell culture-derived HB vaccine or a conventional yeast-derived recombinant HB vaccine, respectively, at 0, 4, and 24 weeks. Data were analyzed from those subjects who received all three inoculations, consisting of 56 student nurses (females aged 19 to 32 years; mean age, 20.9 years) and 23 hospital personnel (females aged 21 to 32 years; mean age, 23 years). The final acquired anti-HBs levels were compared between groups by stratifying the recipients into five titer groups (<100, 100-599, 600-1999, 2000-3999, and ≥4000mIU/mL).In Group M, ≥50% of recipients had antibody levels of ≥4000mIU/mL, whereas in Group B, ≥50% of recipients had antibody levels of either <100 or 100-599mIU/mL, revealing a significantly higher antibody response in Group M than in Group B (p<0.001). The number and rate of observed side effects were compared using 168 and 54 completed post-inoculation questionnaires returned by recipients in Groups M and B, respectively. Systemic symptoms developed in 10 subjects (6.0%) in Group M and three subjects (5.5%) in Group B. Local symptoms developed in 11 subjects (6.5%) in Group M and in 10 subjects (18.5%) in Group B, revealing a significantly higher frequency of local symptoms in Group B (p<0.05). These results demonstrate the effectiveness of this human cell culture-derived HB vaccine.

収録刊行物

  • 環境感染

    環境感染 21 (4), 258-262, 2006

    日本環境感染学会

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ